Click here to view the original press release on PR Newswire.
NEW YORK, Feb. 28, 2018 /PRNewswire/ — The Kinetix Group (TKG) Care Delivery Services has launched a Real World Evidence (RWE) model, focusing on diabetes and cardiovascular conditions. As a part of this initiative, we have partnered with PTS Diagnostics to develop RWE case studies for their technologies, CardioChek Plus and A1CNow. These Point of Care testing devices have the ability to improve quality of care and patient engagement at a system and provider level.
Leveraging our expertise and proven methodology around demonstration design and implementation, TKG is facilitating a multi-phased pilot that will position PTS Diagnostics as a turn-key, technology pioneer at the Point of Care. This program model will demonstrate proof of concept through successful integration of the technology into the pilot sites’ existing clinical workflow.
In partnership with PTS Diagnostics, TKG is committed to enhancing care delivery that ultimately results in a positive impact on the Quadruple Aim outcomes: improved patient experience, patient outcomes, provider experience, and lower cost.
For more information, please contact Harshini Parvatha at firstname.lastname@example.org.
PTS Diagnostics creates health innovation that drives action and connects people to improved outcomes. As a comprehensive point-of-care diagnostics company, PTS designs, manufactures, and markets products for distribution in more than 135 countries around the globe. With an extensive and expanding patent portfolio, PTS Diagnostics’ fingerstick, point-of-care blood collection, diagnostics, and information management products are widely used for testing heart disease, diabetes and more.